Endosomal acidification inhibitors for the treatment of BRAF mutant tumors

Mutations in KRAS and BRAF genes are commonly found in several types of cancer associated with poor prognosis and therapy resistance. We have identified phosphorylated p45-IKKα as an essential mediator of BRAF-induced tumorigenesis. Importantly, endosomal acidification inhibitors preclude phosphoryl...

Descripción completa

Detalles Bibliográficos
Autor principal: Espinosa, Lluís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905373/
https://www.ncbi.nlm.nih.gov/pubmed/27308590
http://dx.doi.org/10.1080/23723556.2015.1062073
Descripción
Sumario:Mutations in KRAS and BRAF genes are commonly found in several types of cancer associated with poor prognosis and therapy resistance. We have identified phosphorylated p45-IKKα as an essential mediator of BRAF-induced tumorigenesis. Importantly, endosomal acidification inhibitors preclude phosphorylation of p45-IKKα and abolish the metastatic capacity of BRAF mutant cancer cells.

Ejemplares similares